BCHT(SH:688276) Cai Jing Wang·2026-01-21 05:54Group 1 - The company expects a net loss attributable to shareholders of 220 million to 280 million yuan for the fiscal year 2025, representing a year-on-year decrease of 194.79% to 220.64% [1] - The expected net loss excluding non-recurring items is projected to be between 240 million to 300 million yuan, with a year-on-year decrease of 204.43% to 230.54% [1] - For the fiscal year 2024, the company anticipates a net profit attributable to shareholders of 232 million yuan and a net profit excluding non-recurring items of 230 million yuan, with earnings per share of 0.56 yuan [1] Group 2 - The sales revenue of the company's herpes zoster live attenuated vaccine has declined due to factors such as the awareness of the disease among potential vaccine recipients and their willingness to receive the vaccine [1] - Some confirmed revenue from the herpes zoster vaccine could not be realized due to expiration before vaccination, leading to returns [1] - The unit price of the herpes zoster vaccine has decreased, contributing to the overall decline in sales revenue year-on-year [1]